Furthermore, the authors develop a small‐molecule inhibitor, NAT10‐2023, which disrupts NAT10's interaction with RNA, reducing ac4C modification levels and suppressing HCC progression. The gene discussed is NAT10; the disease is hepatocellular carcinoma.